Drug · CHEMBL421

SULFASALAZINE

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. SULFASALAZINE. Drugs and targets, record CHEMBL421. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL421

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: SULFASALAZINE; ChEMBL
ChEMBL ID: CHEMBL421; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Azulfidine, Azulfidine en-tabs, Colizine, S.a.s.-500, Salazopyrin, Salazopyrin e.c., Salazopyrin-en, Ucine; ChEMBL
Other names: Benzosulfa, NSC-203730, NSC-667219, SAS-500, Salazosulfapyridine, Salicylazosulfapyridine, Sulfasalazina, Sulfasalazinum, Sulfasalazopyridine, Sulphasalazine; ChEMBL
DrugBank: DB00795; DrugBank
InChIKey: NCEXYHBECQHGNR-QZQOTICOSA-N; ChEMBL
Open Targets' highest stage: Approval, for 4 of its 19 diseases, from DailyMed and TTD; Open Targets

Targets3

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
ALOX5	Polyunsaturated fatty acid 5-lipoxygenase	Arachidonate 5-lipoxygenase inhibitor	INHIBITOR	https://conductscience.org/library/genes/240
PTGS1	Cyclooxygenase	Cyclooxygenase inhibitor	INHIBITOR	https://conductscience.org/library/genes/5742
PTGS2	Cyclooxygenase	Cyclooxygenase inhibitor	INHIBITOR	https://conductscience.org/library/genes/5743

Source ChEMBL

Diseases19

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
rheumatoid arthritis	Approval	DailyMed and TTD	19	15	https://conductscience.org/library/drugs?q=MONDO_0008383
glioblastoma	Phase 1/2	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=MONDO_0018177
juvenile idiopathic arthritis	Approval	DailyMed	4	1	https://conductscience.org/library/drugs?q=MONDO_0011429
acute myeloid leukemia	Phase 1/2	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0018874
adult-onset Still disease	Phase 2	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0019355
alcohol dependence	Unknown	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0007079
alcoholic liver cirrhosis	Unknown	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0006644
ankylosing spondylitis	Phase 3	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0005306
chronic recurrent multifocal osteomyelitis	Unknown	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0009813
colorectal cancer	Phase 3	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0005575

1 to 10 of 19Source Open Targets

See all 19 diseases

Trials59

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT00259610	Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)	Phase 4	755	2014-07-17	sulfasalazine	Its name	ClinicalTrials.gov
NCT00247962	Study Evaluating Etanercept and Sulphasalazine in Ankylosing Spondylitis	Phase 4	566	2012-11-08	sulphasalazine	Its name	ClinicalTrials.gov
NCT01709578	To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)	Phase 3	546	2017-08-08	sulfasalazine	Its name	ClinicalTrials.gov
NCT00848354	Open-Label Study Comparing Etanercept to Conventional Disease Modifying Antirheumatic Drug (DMARD) Therapy	Phase 4	429	2012-04-19	sulfasalazine	Its name	ClinicalTrials.gov
NCT01172639	Effectiveness in Daily Practice of Different Treatment Strategies for Early Rheumatoid Arthritis.	Phase 4	400	2018-12-10	sulfasalazine	Its name	ClinicalTrials.gov
NCT00405275	Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy		353	2013-12-03	sulfasalazine	Its name	ClinicalTrials.gov
NCT00422227	Study Comparing Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis in the Asia Pacific Region	Phase 4	300	2010-08-30	sulfasalazine	Its name	ClinicalTrials.gov
NCT02057250	To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis	Phase 3	217	2017-06-20	sulfasalazine	Its name	ClinicalTrials.gov
NCT03739853	Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial	Phase 4	192	2025-11-26	sulfasalazine	Its name	ClinicalTrials.gov
NCT02374021	Treatments Against RA and Effect on FDG-PET/CT	Phase 4	159	2022-10-26	sulfasalazine	Its name	ClinicalTrials.gov

1 to 10 of 59

See all 59 trials

Comparisons in its trials18

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Etanercept vs Sulphasalazine: Number of Patients Achieving Assessment in Ankylosing Spondylitis (ASAS 20)	287 of 378	99 of 187	565	NCT00247962	Trial comparisons
Triple vs Etanercept: serious adverse events	38 of 222	43 of 219	441	NCT00405275	Trial comparisons
ETN/MTX vs DMARD/MTX: serious adverse events	6 of 197	3 of 103	300	NCT00422227	Trial comparisons
Triple Therapy (MTX+SSZ+HCQ) vs TNF Inhibitor (Etanercept or Adalimumab): deaths from any cause	0 of 80	0 of 79	159	NCT02374021	Trial comparisons
Triple Therapy (MTX+SSZ+HCQ) vs TNF Inhibitor (Etanercept or Adalimumab): serious adverse events	4 of 80	10 of 79	159	NCT02374021	Trial comparisons
Group 1- MTX+LEF+HCQ vs Group 2- MTX+SSZ+HCQ: Number of Patients Achieving Good EULAR Response at the End of 12 Weeks	40 of 68	37 of 68	136	NCT02930343	Trial comparisons
Group 1- MTX+LEF+HCQ vs Group 2- MTX+SSZ+HCQ: deaths from any cause	0 of 68	0 of 68	136	NCT02930343	Trial comparisons
Group 1- MTX+LEF+HCQ vs Group 2- MTX+SSZ+HCQ: serious adverse events	0 of 68	0 of 68	136	NCT02930343	Trial comparisons
Tocilizumab Monotherapy vs Tocilizumab + Methotrexate or Other Non-Biologic DMARDs: serious adverse events	2 of 31	5 of 66	97	NCT01941095	Trial comparisons
Arm I: Sulfasalazine vs Arm II: Placebo: serious adverse events	1 of 43	2 of 42	85	NCT01198145	Trial comparisons

1 to 10 of 18

See all 18 comparisons in its trials

Papers from its trials96

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
34431119	RESULT	1	PubMed
33141955	RESULT	1	PubMed
31819247	RESULT	1	PubMed
27860410	RESULT	1	PubMed
27432356	RESULT	1	PubMed
25889222	RESULT	1	PubMed
25359382	RESULT	1	PubMed
25274892	RESULT	1	PubMed
23908187	RESULT	1	PubMed
23755969	RESULT	1	PubMed

1 to 10 of 96

See all 96 papers from its trials

Tests in its trials0

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL421

GET https://conductscience.org/api/drugs/v1/CHEMBL421/trials?page=2

API reference For AI assistants